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Background. Longitudinal studies have consistently found a significant association between bacterial vaginosis (BV) and acqui-
sition of sexually transmitted diseases. However, there are limited prospective data to confirm these findings.
Methods. We conducted a prospective, randomized, open-label trial of home screening and treatment of young women with
asymptomatic BV who were also at high risk for sexually transmitted diseases. These women were screened every 2 months for
12 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observation alone. The primary
outcome was the incidence of gonorrhea and/or chlamydia.
Results. A total of 1365 subjects were enrolled in the study across 10 sites. Adherence with mailing specimens obtained at home
was excellent in both groups (84%–88%). The incidence of gonorrhea and/or chlamydia was 19.1 per 100 person-years (95% con-
fidence interval, 15.1–22.1) for the treatment group and 18.5 per 100 person-years (15.1–22.8) for the observation arm, a difference
that was not statistically significant.
Conclusions. Young women were very amenable to home screening for BV, gonorrhea, and chlamydia. Treatment of asymp-
tomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhea and/or chlamydia.
Clinical Trials Registration. NCT00667368.
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Bacterial vaginosis (BV) is characterized by a shift in the vaginal
bacterial flora from lactobacillus predominant to lactobacilli de-
pleted and high concentrations of bacteria such as Gardnerella
vaginalis, and anaerobes [1].Although BVmay cause symptoms
of vaginal discharge and odor, a significant number of women
are asymptomatic [2, 3]. Currently, treatment is not recom-
mended for the latter group [4]. BV is significantly associated
with acquisition of sexually transmitted diseases (STDs), in-
cluding chlamydia and gonorrhea [5–8], but there have been
few published clinical trials to determine whether screening
and treatment of asymptomatic BV will reduce this risk [9].
We conducted a clinical trial to determine whether regular
screening and treatment for asymptomatic BV reduces the 1-
year incidence of chlamydia and gonorrhea.
METHODS
Women aged 15–25 years were recruited from 10 sites (STD,
family planning, obstetrics-gynecology, and clinical research
clinics) in 6 geographic locations (Baltimore, Maryland; Birming-
ham, Alabama; Durham and Raleigh, North Carolina; Pittsburgh,
Pennsylvania; and San Francisco, California). All sites were ap-
proved to conduct the study by their local institutional review
boards. To qualify for participation, women must have had vag-
inal intercourse in the past 3 months and also had ≥2 of the fol-
lowing risk factors for STDs: age ≤20 years, African American
race, Hispanic ethnicity, douching at least once per month, ≥2
sex partners in the past 12 months, and STD diagnosis in the
past year (self-reported or from clinic notes) [10–12]. These cri-
teria were designed to ensure that subjects were at increased risk
for STDs. In addition, participants had to have asymptomatic BV,
defined as having 2 of the 4 clinical criteria commonly used to
diagnose BV (vaginal pH >4.5% and >20% clue cells on vaginal
wet preparation microscopy) and no endorsement of abnormal
vaginal discharge or odor. Compared with microbiological crite-
ria for BV (Nugent criteria), elevated pH and clue cells have a spe-
cificity of 92%; thus, most women with these 2 criteria would
meet criteria for BV [13]. Women were excluded if they were
pregnant, used antibiotics daily, lived with their sexual partner
(due to lower risk of future STDs), were homeless, were unwilling
to abstain from alcohol during treatment, were allergic to metro-
nidazole, had seizure disorder or liver disease, took cimetidine or
warfarin, had undergone hysterectomy, were currently menstru-
ating, or had trichomoniasis in addition to BV.
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Recruitment
Women were informed about the study by contact with a re-
cruiter working in the community, referral from a clinician,
or a study brochure. Some participating clinics conducted wet
mount screening of asymptomatic women as part of routine
care, and women with asymptomatic BV were asked if they
were interested in the study. At other sites, a screening informed
consent was obtained to determine whether the woman had
asymptomatic BV. Screening was conducted from vaginal
swabs that were either self-obtained after receiving instruction
from study staff or obtained by the clinician. For women with
asymptomatic BV who were interested in the study, full in-
formed consent was obtained, followed by assessment of all el-
igibility criteria.
Randomization
Women were randomized into either the treatment group or the
control group (observation), using a computer-generated block
randomization scheme stratified by site. Assignments were con-
cealed using sealed envelopes at each site. Women randomized
to treatment were provided oral metronidazole at enrollment,
500 mg twice daily for 7 days. When a follow-up home-testing
sample was positive for BV (Nugent score, 7–10 [14]), subjects
in the treatment group were informed of their results and pro-
vided the same 7-day treatment for BV either by mail or by
pick-up at the clinic. Women in the control group did not re-
ceive notification of BV status or treatment for BV, which is
consistent with usual care for asymptomatic BV. Subjects in
both groups were encouraged to see their healthcare provider
if they developed genitourinary symptoms, and women were al-
lowed to receive any recommended treatments received outside
the study protocol. Women in both groups with positive chla-
mydia and/or gonorrhea results were notified and referred to a
healthcare provider or a public STD clinic to receive treatment.
This was an open-label study; however, the primary end point,
positive chlamydia and/or gonorrhea results, was determined at
central laboratories that were masked to randomization
assignment.
Enrollment and Follow-up
At enrollment, subjects completed a baseline questionnaire to
assess demographic factors, sexual risk behavior, contraceptive
methods, and health history. Subjects provided 2 vaginal swabs
(self-obtained or obtained by a clinician). One swab was
rolled across a microscope slide, and another was placed in a
transport tube for gonorrhea and chlamydia testing. Subjects re-
ceived a home testing kit in the mail every 2 months for 12
months, including 2 vaginal swabs, an instruction sheet for
swab collection, a microscope slide and holder, and a prela-
beled, stamped return envelope. For BV evaluation, women ob-
tained a vaginal swab sample and rolled the swab across a
prelabeled glass slide in a prepackaged slide holder. Self-testing
for BV with vaginal swabs has excellent reliability and validity
compared with clinician-obtained swabs [15, 16]. Swabs for
chlamydia and gonorrhea testing were provided at 4, 8, and
12 months after study entry. With each home testing kit, sub-
jects completed a brief survey that assessed sexual risk behavior,
contraceptive use, as well as any treatment for BV outside the
study. We did not collect information about symptoms with
the follow-up testing. Subjects mailed their specimens and
questionnaires through the US mail to the study laboratory.
In the laboratory, slides were interpreted for Nugent score by
technicians blinded to treatment assignment, swabs were tested
for chlamydia and gonorrhea using the BDProbeTec assay, and
study questionnaires were sent to the central data management
site. Study research staff regularly contacted subjects to remind
them to send in the testing kits. Subjects received a financial
incentive for each follow-up kit submitted. The laboratory
notified research staff of results from BV, chlamydia, and gon-
orrhea testing.
Sample Size Calculations
The planned enrollment was 1500 eligible subjects, from which
1200 were expected to complete the study, reflecting an expect-
ed loss to follow-up rate of 20%. Sample size and power calcu-
lations were based on the primary study outcome: the 1-year
STD infection rate which counted each occurrence of a positive
chlamydia or gonorrhea infection during the follow-up period
in estimating the infection rate. This approach allowed the dis-
tinction between women who had a single STD and those who
had multiple positive STD tests. We considered a 2-sided signif-
icance level (α value) of .05; an estimated proportion of 15% and
20% of subjects in the treatment and observation groups, re-
spectively, having any chlamydial and gonococcal infections
during the 12-month follow-up; and an estimated 30% of sub-
jects with 1 STD who would acquire an additional infection
during the follow-up period. Assuming the STD incidence
rate above and a Poisson distribution, the study had >80%
power to detect an absolute difference of 7 infections per 100
person-years in STD incidence rates (13 vs 20 infections per
100 person-years). The cumulative proportion of subjects who
had ≥1 STD detected was estimated for both groups using the
Kaplan–Meier method, and its 95% confidence interval (CI)
was estimated using Greenwood’s formula and compared
using log-rank tests. The sample size had >90% power to detect
a 5% difference in the cumulative proportion of persons with an
STD (10% vs 15%) at 12 months.
Interim Analyses
Interim analyses were prespecified and conducted after one-
third and two-thirds of the study subjects had completed
study participation, with stopping rules for superiority based
on the Lan-DeMets spending function with the O’Brien-Fleming
boundary to maintain an overall .05 significance level. In July
2013, an ad hoc meeting of the Data and Safety Monitoring
Board was held to review accrual and to discuss results from a
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futility analysis based on 1265 subjects. The Board recommend-
ed that recruitment be terminated because further accrual
would not significantly contribute to the outcome of the study.
Statistical Analysis Plan
To assess the primary study outcome, the incidence of chlamyd-
ia and/or gonorrhea in the 2 groups was estimated as Poisson
rates, and the difference between them tested for statistical sig-
nificance at the .05 significance level. In addition, the Cox pro-
portional hazards model was used to compare the time to first
STD. The event time was considered the midpoint between the
date of the positive test collection and the date of prior test col-
lection, with the exception of baseline. Baseline STDs were not
included in the incidence rate calculation. Subject characteris-
tics and the proportion of subjects experiencing adverse events
were compared according to arm using the Cochran–Mantel–
Haenszel test stratified by site (categorical variables) or analysis
of variance with adjustment for site (continuous variables). The
primary analysis population for efficacy and safety was the
intent-to-treat (ITT) population, which included all subjects
randomized. Confirmatory analyses was performed with the
per-protocol (PP) population, which was defined as all random-
ized subjects who completed 12 months of follow-up and re-
turned ≥4 of the 6 home testing kits. This definition was
based on the assumption that 100% adherence with kits was un-
likely; thus, it was decided to include those who adhered the
majority of the time.
RESULTS
Enrollment Data
There were 1370 enrollments to the study; however, 5 subjects
were enrolled twice and data from their second enrollment was
removed from both ITT and PP populations, leaving 1365 sub-
jects in the ITT population. Of these, 986 subjects met criteria
for the PP population. Of 1365 subjects enrolled in the trial
(Figure 1), 683 were randomized to treatment and 682 to obser-
vation. Owing to early discontinuation or loss to follow-up of
172 treatment subjects and 200 observation subjects, 511
(74.8%) and 482 (70.7%) completed the study, respectively.
The early discontinuation or loss to follow-up rate was 25%
for the treatment arm and 29% for the observation arm
(P = .09). The median number of visits was 7 for both arms
(P = .76). Comparison of women who completed the study
with those who discontinued early showed the latter to be
slightly younger (20.8 vs 21.4 years; P = .04) and to have signifi-
cantly higher rates of STD at the baseline visit (1% vs 3%;
P = .004). Regardless of completion status, data from all evalu-
able visits for all randomized subjects were analyzed in the
ITT analysis. Table 1 shows the baseline characteristics of the
ITT population stratified by study arm. The 2 arms did not sig-
nificantly differ in terms of baseline subject characteristics. At
Figure 1. Participant flow. BV, bacterial vaginosis.
Table 1. Baseline Characteristics
Characteristic
All Subjects
(N = 1365)
BV Treatment
(n = 683)
Observation
(n = 682)
P
Valuea
Age, mean (SD), y 21 (2) 21 (2) 21(2) .93
Race, No. (%)
Black 1065 (78) 530 (78) 535 (78) .09
White 110 (8) 65 (10) 45 (7)
Otherb 190 (14) 88 (13) 102 (15)
Times ever treated for BV, No. (%)
0 756 (55) 385 (56) 371 (54) .12
1 272 (20) 123 (18) 149 (22)
2–4 242 (18) 123 (18) 119 (17)
≥5 75 (5) 45 (7) 30 (4)
Unknown 20 (1) 7 (1) 13 (2)
No. of vaginal sex partners, No. (%)
0 86 (6) 42 (6) 44 (6) .73
1 646 (47) 328 (48) 318 (47)
≥2 633 (46) 313 (46) 320 (47)
New sexual partners in past year, No. (%)
No 680 (50) 335 (49) 345 (51) .56
Yes 685 (50) 348 (51) 337 (49)
BV results, No. (%)c
BV present (NS, 7–10) 1192 (87) 598 (88) 594 (87) .37
Intermediate flora
(NS, 4–6)
140 (10) 74 (11) 66 (10)
Normal flora (NS, 0–3) 24 (2) 9 (1) 15 (2)
Missing 8 (1) 2 (<1) 6 (1)
Gonorrhea, No. (%)c
Positive 63 (5) 37 (5) 26 (4) .15
Negative 1301 (95) 646 (95) 655 (96)
Chlamydia, No. (%)c .81
Positive 191 (14) 94 (14) 97 (14)
Negative 1173 (86) 589 (86) 584 (86)
STD, No. (%)c
Both gonorrhea and
chlamydia
22 (2) 12 (2) 10 (1) .86
Gonorrhea or
chlamydia
210 (15) 107 (16) 103 (15)
Neither 1132 (83) 564 (83) 568 (83)
Abbreviations: BV, bacterial vaginosis; NS, Nugent score; SD, standard deviation; STD,
sexually transmitted disease.
a Analysis of variance adjusting for site (age) or stratified (by site) Cochran–Mantel–Haenszel
test.
b The “Other” category comprised multiracial (n = 102), missing race (n = 55), Hawaiian/
Pacific Islander (n = 13), Asian (n = 16), and Native American (n = 4).
c The total for these categories is 1364 instead of 1365 because baseline laboratory data
were lost for 1 participant.
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follow-up visits, kit completion rate ranged from 84% to 88%
across arms, with no difference in adherence between treatment
arms (Figure 2).
1-Year Incidence of Chlamydia and Gonorrhea
The 1-year incidence rate of gonorrhea or chlamydia was 18.3
(95% CI, 15.1–22.1) per 100 person-years for the BV treatment
arm and 19.2 (15.9–23.2) per 100 person-years for the observa-
tion arm in the ITT population (Table 2). This risk difference of
−0.9 (95% CI, −12.0 to 10.1) was not statistically significant
(P = .75). The cumulative proportion of subjects with a diagno-
sis of gonorrhea and/or chlamydia infection by 12 months was
11.7 (95% CI, 9.3–14.7) for the BV treatment arm and 12.2
(9.7–15.3) for the observation arm (P = .80). Twenty-three sub-
jects (2%) had multiple visits with a positive STD test. There
was no difference in reported regular use of condoms during
the course of the study, with 22% reporting regular use in the
treatment arm versus 24% in the control arm.
Prevalence of BV
The proportion of subjects with BV at any follow-up visit dif-
fered significantly according to study arm, with ≥1 diagnosis of
BV occurring in 83% of subjects in the BV treatment arm and
93% in the observation arm (P < .001). Considering the pres-
ence of BV across all visits, after adjustment for the prior visit’s
BV test result, age, race/ethnicity, and sexual history, the odds of
BV being diagnosed at a follow-up visit in the treatment arm
was nearly half that in the observation arm (odds ratio, 0.53;
95% CI, .46–.61; P < .001) (Figure 3). There was no significant
difference in the percentage of women who reported treatment
for BV outside the study protocol (11% vs 13% in the treatment
and observation arms, respectively; P = .15).
Analysis of Safety Data
There were 9 and 3 serious adverse events in the BV treatment
and observation arms, respectively. None of these was deemed
to be associated with use of metronidazole. The most common
adverse event was vulvovaginal candidiasis, reported by 3% of
subjects in both arms, and urinary tract infections, reported by
2% in the treatment arm and 3% in the observation arm. Thirty
subjects (4.4%) experienced gastrointestinal events in the treat-
ment arm and 12 (1.8%) in the observation arm (P = .005).
DISCUSSION
BV is the most common form of vaginitis and is linked to seri-
ous sequelae, such as preterm birth and acquisition/transmis-
sion of STD [8, 17, 18]. Although treatment recommendations
differentiate between women who report symptoms and those
who do not [4], this differentiation is probably somewhat arbi-
trary. In a large study of vaginal flora patterns, 63% of women
with BV denied having vaginal discharge and/or odor and the
difference in reported vaginal symptoms between women with
and without BV was small [3]. To our knowledge, there are no
published studies on differences in sequelae between asymp-
tomatic and symptomatic BV. However, adverse outcomes
linked to BV are probably caused by alterations in the vaginal
flora that are seen in both [18, 19]. Current recommendations
for withholding therapy for asymptomatic BV allowed us to eth-
ically randomize women to observation alone [4].
We hypothesized that screening and treatment for asymp-
tomatic BV would prevent STDs by restoring optimal vaginal
flora, thus reducing susceptibility to STDs. This hypothesis is
supported by studies consistently demonstrating an associa-
tion between BV and an increased prevalence and incidence
Figure 2. Adherence to kit collection.
Table 2. Sexually Transmitted Disease Follow-up Event Rates and Intent-to-Treat Population Total Follow-up for the Cohort (1137.4 Person-years in 1365
Subjects)
Randomization Arm
Gonorrhea Chlamydia Gonorrhea or Chlamydia
BV Treatment
(n = 683)
No BV Treatment
(n = 682)
BV Treatment
(n = 683)
No BV Treatment
(n = 682)
BV Treatment
(n = 683)
No BV Treatment
(n = 682)
Total follow-up, person-years 580.0 557.4 580.0 557.4 580.0 557.4
Total visits with any STD, No. 26 19 80 88 106 107
Rate per 100 person-years (95% CI) 4.5 (3.1–6.6) 3.4 (2.2–5.3) 13.8 (11.1–17.2) 15.8 (12.8–19.5) 18.3 (15.1–22.1) 19.2 (15.9–23.2)
Rate difference (95% CI) 1.1 (−4.0 to 6.1) (P = .46) −2.0 (−11.8 to 7.8) (P = .47) −0.9 (−12.0 to 10.1) (P = .75)
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; STD, sexually transmitted disease.
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of STDs and human immunodeficiency virus (HIV) infection
[6–8, 20, 21].
We are aware of only 2 prospective studies addressing wheth-
er treatment of asymptomatic BV prevents STD acquisition [9].
In one trial, treatment of BV with metronidazole gel followed by
twice-weekly gel as BV prophylaxis reduced the incidence of
chlamydia [9]. A recent, secondary analysis from a trial of intra-
vaginal metronidazole and miconazole [22], showed a trend to-
ward lower incidence of chlamydia and gonorrhea in the
treatment arm compared with the placebo arm [23].
Although STDs were common in our study, (nearly 20 infec-
tions/100 woman-years), we found no difference in the inci-
dence of chlamydia or gonorrhea during 1 year of follow-up.
Women randomized to treatment for asymptomatic BV had
lower rates of future BV, an expected finding. The lack of re-
duction in the incidence of chlamydia and gonorrhea suggests
either that asymptomatic BV is not causally linked to a woman’s
increased risk of STDs or that cure rates with metronidazole or
duration of cure were insufficient to protect against STDs. In
terms of risk associated with treatment of asymptomatic BV,
we found that the overall rate of adverse events was low and
did not differ substantially between treatment and observation
arms, except for gastrointestinal side effects.
Several limitations of our study warrant mention. It was not
possible to blind participants or local research staff to random-
ization arm. However, we do not believe that this knowledge
would affect a participant’s risk of acquiring an STD. Laborato-
ry staff evaluating the main outcome were blind to study assign-
ment. We do not have information on adherence to treatment
with metronidazole among women in the treatment arm. Lack
of adherence to a treatment regimen is an issue on clinical trials
as demonstrated in a study of preexposure prophylaxis for HIV
infection [24]. Adherence in our study may have been affected
by the fact that these women had no symptoms to alleviate as
well as by the unpleasant taste of metronidazole. Although
the study conducted testing for chlamydia and gonorrhea
every 4 months, we did not obtain information regarding chla-
mydial or gonococcal infections diagnosed outside the trial. In
another trial of home screening for chlamydia and gonorrhea,
subjects received an average of 1 to 2 STD tests per year outside
the testing protocol [25]. However, the nearly identical rates of
STD diagnoses within our trial make it unlikely that a signifi-
cant difference in overall STD rates would be found, even if
these additional test results were known and included. Further-
more, this analysis only considered the effect of BV treatment
on chlamydial and gonococcal infections and did not include
other STDs, such as trichomonas or HIV infection.
In summary, this is the largest study to ever evaluate the im-
pact of treatment of BV on STD outcomes and demonstrated
that women were very compliant with the submission of self-
collected vaginal specimens mailed every 2 months. However,
based on this study, treatment of asymptomatic BV with oral
metronidazole does not affect the incidence of gonorrhea or
chlamydia. If more effective therapies for BV become available,
consideration should be given to revisiting this approach.
Notes
Acknowledgments. We gratefully acknowledge the support of Jonathan
Glock, National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Project Manager.
Financial support. This work was supported by the Division of
Microbiology and Infectious Diseases of the NIAID (contract
HHSN26620040073C).
Potential conflicts of interest. All authors: No reported conflicts. All
authors have submitted the ICMJE Form for Disclosure of Potential Con-
flicts of Interest. Conflicts that the editors consider relevant to the content
of the manuscript have been disclosed.
References
1. Hillier SL. Diagnostic microbiology of bacterial vaginosis. Am J Obstet Gynecol
1993; 169:455–9.
2. Eschenbach DA, Hillier S, Critchlow C, Stevens C, DeRouen T, Holmes KK. Diag-
nosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988;
158:819–28.
3. Klebanoff MA, Schwebke JR, Zhang J, Nansel TR, Yu KF, Andrews WW. Vulvo-
vaginal symptoms in women with bacterial vaginosis. Obstet Gynecol 2004;
104:267–72.
4. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines,
2015. MMWR Recomm Rep 2015; 64:1–137.
5. Ness RB, Kip KE, Soper DE, et al. Bacterial vaginosis (BV) and the risk of incident
gonococcal or chlamydial genital infection in a predominantly black population.
Sex Transm Dis 2005; 32:413–7.
6. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis
is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infec-
tion. Clin Infect Dis 2003; 36:663–8.
7. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora,
and risk of human immunodeficiency virus type 1 and sexually transmitted disease
acquisition. J Infect Dis 1999; 180:1863–8.
8. Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by
Gram stain and diminished colonization resistance to incident gonococcal, chla-
mydial, and trichomonal genital infection. J Infect Dis 2010; 202:1907–15.
9. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic
bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J
Obstet Gynecol 2007; 196:517.e1–6.
10. Gaydos CA, Howell MR, Pare B, et al. Chlamydia trachomatis infections in female
military recruits. N Engl J Med 1998; 339:739–44.
11. Stergachis A, Scholes D, Heidrich FE, Sherer DM, Holmes KK, StammWE. Selec-
tive screening for Chlamydia trachomatis infection in a primary care population of
women. Am J Epidemiol 1993; 138:143–53.
Figure 3. Acquisition, recurrence, and persistence of bacterial vaginosis (BV).
Screening for Bacterial Vaginosis to Prevent STDs • CID 2016:62 (1 March) • 535
12. Tsai CS, Shepherd BE, Vermund SH. Does douching increase risk for sexually
transmitted infections? a prospective study in high-risk adolescents. Am J Obstet
Gynecol 2009; 200:38.e1–8.
13. Gutman RE, Peipert JF, Weitzen S, Blume J. Evaluation of clinical methods for di-
agnosing bacterial vaginosis. Obstet Gynecol 2005; 105:551–6.
14. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is
improved by a standardized method of Gram stain interpretation. J Clin Microbiol
1991; 29:297–301.
15. Nelson DB, Bellamy S, Gray TS, Nachamkin I. Self-collected versus provider-
collected vaginal swabs for the diagnosis of bacterial vaginosis: an assessment of
validity and reliability. J Clin Epidemiol 2003; 56:862–6.
16. Strauss RA, Eucker B, Savitz DA, Thorp JM Jr. Diagnosis of bacterial vaginosis
from self-obtained vaginal swabs. Infect Dis Obstet Gynecol 2005; 13:31–5.
17. Eschenbach DA. The role of bacterial vaginosis as a cause of amniotic fluid infection,
chorioamnionitis and prematurity—a review. Arch Gynecol Obstet 1993; 16:S282–7.
18. Hillier S. The vaginal microbiol ecosystem and resistance to HIV. AIDS 1998;
14:17–21.
19. Eschenbach DA. Bacterial vaginosis and anaerobes in obstetric-gynecologic infec-
tion. Clin Infect Dis 1993; 16(suppl 4):S282–7.
20. Balkus JE, Richardson BA, Rabe LK, et al. Bacterial vaginosis and the risk of trich-
omonas vaginalis acquisition among HIV-1-negative women. Sex Transm Dis
2014; 41:123–8.
21. Gallo MF, Macaluso M, Warner L, et al. Bacterial vaginosis, gonorrhea, and chla-
mydial infection among women attending a sexually transmitted disease clinic: a
longitudinal analysis of possible causal links. Ann Epidemiol 2012; 22:213–20.
22. McClelland RS, Balkus JE, Lee J, et al. Randomized trial of periodic presumptive
treatment with high-dose intravaginal metronidazole and miconazole to prevent
vaginal infections in HIV-negative women. J Infect Dis 2015; 211:1875–82.
23. Balkus J, Anzala O, Kimani J, et al. Periodic presumptive treatment for vaginal in-
fections may reduce chlamydia and gonorrhea incidence: a secondary analysis
from the Preventing Vaginal Infections trial. In: World STI and HIV Congress,
Brisbane, Australia, 13–16 September 2015.
24. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure
prophylaxis for HIV infection among African women. N Engl J Med 2015;
372:509–18.
25. Cook RL, Ostergaard L, Hillier SL, et al. Home screening for sexually transmitted
diseases in high-risk young women: randomised controlled trial. Sex Transm In-
fect 2007; 83:286–91.
536 • CID 2016:62 (1 March) • Schwebke et al
